Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Figure 2 Serum liver enzyme activities in patients enrolled in the study and included in groups treated with the sodium-glucose co-transporter-2 inhibitors or other glucose-lowering drugs before (T0) and after 1 wk of treatment (T1). A: Serum aspartate aminotransferase; B: Serum alanine aminotransferase; C: Serum gamma-glutamyl transpeptidase activities in patients observed in the study, grouped according to the assigned treatment. Data in the graphs are represented as mean ± SEM. Two-way analysis of variance and Tukey assessed statistical differences as posthoc test. ^aP < 0.05. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; Gamma-GT: Gamma-glutamyl transpeptidase; SGLT2-I: Sodium-glucose co-transporter-2 inhibitor; OTHER: Other glucose lowering drug.